Cargando…

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma

Multiple myeloma (MM) remains to be incurable despite recent therapeutic advances. CD47, an immune checkpoint known as the “don’t eat me” signal, is highly expressed on the surface of various cancers, allowing cancer cells to send inhibitory signals to macrophages and impede phagocytosis and immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jennifer, Muz, Barbara, Alhallak, Kinan, Markovic, Matea, Gurley, Shannon, Wang, Zhe, Guenthner, Nicole, Wasden, Katherine, Fiala, Mark, King, Justin, Kohnen, Daniel, Salama, Noha Nabil, Vij, Ravi, Azab, Abdel Kareem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072283/ https://www.ncbi.nlm.nih.gov/pubmed/32012878 http://dx.doi.org/10.3390/cancers12020305

Ejemplares similares

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020)

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2021)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

Targeting E-selectin to Tackle Cancer Using Uproleselan
por: Muz, Barbara, et al.
Publicado: (2021)

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023)

Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
por: Alhallak, Kinan, et al.
Publicado: (2021)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
por: Muz, Barbara, et al.
Publicado: (2015)

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells
por: Muz, B, et al.
Publicado: (2014)

Evolution and structure of clinically relevant gene fusions in multiple myeloma
por: Foltz, Steven M., et al.
Publicado: (2020)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
por: Mian, Hira, et al.
Publicado: (2023)

High dose therapy and autologous stem cell transplant in older adults with multiple myeloma
por: Wildes, Tanya M, et al.
Publicado: (2015)

Targeted treatments for multiple myeloma: specific role of carfilzomib
por: Sugumar, Dhivya, et al.
Publicado: (2015)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
por: Barnell, Erica K., et al.
Publicado: (2022)

The myeloid binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting
por: Lu, Zhi Hong, et al.
Publicado: (2014)

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma
por: Liu, Yang, et al.
Publicado: (2013)

Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival
por: Hathi, Deep, et al.
Publicado: (2022)

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
por: Weisberg, Ellen, et al.
Publicado: (2022)

Co-evolution of tumor and immune cells during progression of multiple myeloma
por: Liu, Ruiyang, et al.
Publicado: (2021)

Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
por: Yao, Lijun, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Sex chromosome aneuploidies and fertility: 47,XXY, 47,XYY, 47,XXX and 45,X/47,XXX
por: Rogol, Alan D
Publicado: (2023)

Mucormycosis: A potential head and neck problem in COVID‐19 patients
por: Abdel‐Aziz, Mosaad, et al.
Publicado: (2022)

47XXY and 47XXX in Scleroderma and Myositis
por: Scofield, R. Hal, et al.
Publicado: (2022)

Degradation Mechanisms of 4,7-Dihydroxycoumarin Derivatives in Advanced Oxidation Processes: Experimental and Kinetic DFT Study
por: Milanović, Žiko, et al.
Publicado: (2023)

Exploring the landscape of aesthetic pharmacy practice
por: Alhallak, Kamal
Publicado: (2023)

Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells
por: Alhallak, Kinan, et al.
Publicado: (2017)

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
por: White, Brian S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nbg47p0d6p0o5s6el2q8nohctr